רישום פעילות עצבית קורטיקלית ותת-קורטיקלית באמצעות מערכות אלקטרודות

Executive Industry Relevance

Simultaneous cortical and subcortical neuronal recording enables mechanistic de-risking in target validation by clarifying brain-wide signal propagation during cognitive tasks. This approach supports predictive confidence in neuropsychiatric drug discovery by linking cortical readouts to deep brain activity. It informs portfolio decisions on CNS-targeted therapeutics through translational biomarker alignment.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by mapping cortical-subcortical network engagement during attention-based tasks.
• Operational Value: Enables biological de-risking of targets through direct measurement of LFP and EEG correlates of neuronal activation.
• Predictive Value: Supports target confidence by quantifying signal transmission across brain regions in response to visual stimuli.

Screening & Assay Development

• Assay Readiness: Prepares validated neurophysiological systems for compound screening by establishing baseline LFP and EEG responses to visual stimulation.
• Quantitative Output: Delivers synchronized LFP and EEG measurements enabling dose-response analysis of CNS-active compounds.
• Reproducibility: Standardizes electrode placement via the 10-20 system and stimulus timing for cross-lab consistency in biomarker validation.

Translational & Preclinical Research

• Disease Relevance: Models human cognitive and emotional flanker task performance to align with clinical endpoints in neuropsychiatric indications.
• Translational Continuity: Bridges discovery-phase target modulation with preclinical validation through conserved neural circuit readouts.
• Risk-Adjusted Advancement: Informs go/no-go decisions by detecting off-target effects on subcortical processing during cortical-targeted interventions.

Pipeline & Workflow Integration

This method integrates into the discovery continuum from target hypothesis testing through lead identification to preclinical efficacy assessment by providing objective neurophysiological readouts.

• Discovery Biology: Supports pathway clarification by revealing how visual stimuli propagate from cortical to subcortical networks during cognitive engagement.
• Screening: Enables assay readiness through stable, time-locked LFP and EEG recordings that detect compound-induced alterations in neural synchrony.
• Analytics: Provides quantitative LFP amplitude and EEG power metrics that allow comparison of drug effects on cortical versus subcortical activity.
• Translational Research: Connects to preclinical work via conserved flanker task analogs in animal models for cross-species biomarker validation.
• Enterprise Reuse: Establishes a reusable neurophysiological platform for evaluating multiple CNS targets across therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in target validation by directly measuring engagement of distributed brain networks.
• Operational Value: Ensures reproducibility through standardized EEG setup, stimulus timing, and electrode referencing protocols.
• Strategic Value: Improves capital efficiency by identifying biologically active compounds early, reducing failure in later stages due to lack of target engagement.
• Portfolio Impact: Enables risk-adjusted prioritization of CNS candidates based on concordant cortical and subcortical response profiles.

Implementation Considerations

• Requires expertise in electrophysiology, neuroanatomy, and human participant safety for invasive and surface electrode handling.
• Dependent on EEG control boxes capable of simultaneous high-bandwidth LFP and EEG recording with precise trigger synchronization.
• Necessitates cross-team standardization between neuroscience, assay development, and data analysis groups for consistent biomarker interpretation.
• Involves adaptation considerations when translating human flanker task paradigms to animal models or alternative cognitive assays.
• Limited by participant availability with implanted DBS electrodes, restricting scalability for high-throughput screening without surrogate models.

Biopharma FAQs